APRE vs. ONCT, KALA, GDTC, BFRG, BIVI, LUMO, NRSN, ITRM, NRBO, and INDP
Should you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Oncternal Therapeutics (ONCT), KALA BIO (KALA), CytoMed Therapeutics (GDTC), Bullfrog AI (BFRG), BioVie (BIVI), Lumos Pharma (LUMO), NeuroSense Therapeutics (NRSN), Iterum Therapeutics (ITRM), NeuroBo Pharmaceuticals (NRBO), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical preparations" industry.
Aprea Therapeutics (NASDAQ:APRE) and Oncternal Therapeutics (NASDAQ:ONCT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership.
Aprea Therapeutics has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -5,029.17%. Aprea Therapeutics' return on equity of -61.06% beat Oncternal Therapeutics' return on equity.
34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 16.1% of Oncternal Therapeutics shares are owned by institutional investors. 20.9% of Aprea Therapeutics shares are owned by company insiders. Comparatively, 8.0% of Oncternal Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Aprea Therapeutics had 12 more articles in the media than Oncternal Therapeutics. MarketBeat recorded 13 mentions for Aprea Therapeutics and 1 mentions for Oncternal Therapeutics. Oncternal Therapeutics' average media sentiment score of 1.89 beat Aprea Therapeutics' score of 0.05 indicating that Oncternal Therapeutics is being referred to more favorably in the news media.
Oncternal Therapeutics has higher revenue and earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Oncternal Therapeutics, indicating that it is currently the more affordable of the two stocks.
Aprea Therapeutics received 18 more outperform votes than Oncternal Therapeutics when rated by MarketBeat users. Likewise, 51.72% of users gave Aprea Therapeutics an outperform vote while only 31.76% of users gave Oncternal Therapeutics an outperform vote.
Aprea Therapeutics presently has a consensus target price of $15.50, indicating a potential upside of 155.35%. Oncternal Therapeutics has a consensus target price of $32.00, indicating a potential upside of 290.24%. Given Oncternal Therapeutics' higher probable upside, analysts plainly believe Oncternal Therapeutics is more favorable than Aprea Therapeutics.
Aprea Therapeutics has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Oncternal Therapeutics has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.
Summary
Aprea Therapeutics beats Oncternal Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Aprea Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Aprea Therapeutics Competitors List
Related Companies and Tools